HIPRA, S.A.

HIPRA, S.A. is a global biotechnological pharmaceutical company specializing in the research, production, and commercialization of innovative vaccines and diagnostic solutions for animal and human health. Headquartered in Amer, Girona, Spain, the company operates across 40 operating and distribution subsidiaries with a commercial presence in more than 100 countries. With over 50 years of experience in biotechnology, HIPRA controls all phases of vaccine development, maintaining three R&D centers, six production plants, and eleven diagnostic centers worldwide. The company serves livestock producers, veterinarians, and companion animal owners by providing vaccines for swine, poultry, ruminants, aquaculture, rabbits, and dogs. Key animal health product brands include ICTHIOVAC, RESPIVAC, DIVENCE PENTA, YURVAC RHD, EVANOVO, MHYOSPHERE PCV ID, and GUMBOHATCH. In human health, HIPRA develops advanced recombinant protein COVID-19 vaccines and specialized diagnostic tools for digestive health through its GoodGut division. Additionally, the organization offers Contract Development and Manufacturing Organization (CDMO) services, tailored autovaccines, and advanced data-driven diagnostic support. Backed by a multidisciplinary workforce of more than 2,400 employees, HIPRA is dedicated to advancing the global One Health initiative through preventive medicine.